BioCryst Pharmaceuticals (NASDAQ:BCRX) said a late-stage study testing the intravenous form of its experimental influenza drug peramivir showed the drug was not inferior to another flu drug, Tamiflu, sending its shares up 50 percent.

Analysts are expecting a favorable decision from U.S. health regulators on the additional use of Spectrum Pharmaceuticals' (NASDAQ:SPPI) cancer drug Zevalin as a first-line therapy for non-Hodgkin's lymphoma (NHL), which will give a much-needed boost...